New #JCI_insight paper: Mechanistic diversity within RLC-dependent myosin ATPase inhibitors differentiates EDG-7500, a diastolic-selective cardiac sarcomere modulator. #Myoblue tinyurl.com/56npu46y
JCI Insight -
Mechanistic diversity within RLC-dependent myosin ATPase inhibitors differentiates EDG-7500, a diastolic-selective cardiac sarcomere modulator
tinyurl.com
September 22, 2026 at 6:47 PM
New #JCI_insight paper: Mechanistic diversity within RLC-dependent myosin ATPase inhibitors differentiates EDG-7500, a diastolic-selective cardiac sarcomere modulator. #Myoblue tinyurl.com/56npu46y
Wow, these Phase 2 results for EDG-7500 in HCM (a thickened heart muscle condition) really caught my eye. 90% of obstructive HCM patients improved. Crucially, it didn't lower LVEF (the heart's pumping ability), a common safety issue with other treatments.
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with ED
Edgewise Therapeutics has reported positive Phase 2 results for its experimental drug EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy (HCM). The trial showed the drug improved
www.prnewswire.com
June 17, 2026 at 8:05 PM
Wow, these Phase 2 results for EDG-7500 in HCM (a thickened heart muscle condition) really caught my eye. 90% of obstructive HCM patients improved. Crucially, it didn't lower LVEF (the heart's pumping ability), a common safety issue with other treatments.
Edgewise Therapeutics Reveals EDG-7500's Unique Mechanism to Treat Heart Disease#United_States#Boulder#Heart_Disease#EDG-7500#Edgewise
Edgewise Therapeutics Reveals EDG-7500's Unique Mechanism to Treat Heart Disease
Edgewise Therapeutics announces the innovative mechanism of action for EDG-7500, offering hope for patients with hypertrophic cardiomyopathy through improved cardiac relaxation.
third-news.com
September 22, 2026 at 11:12 AM
Edgewise Therapeutics Reveals EDG-7500's Unique Mechanism to Treat Heart Disease#United_States#Boulder#Heart_Disease#EDG-7500#Edgewise
Shares of Edgewise Therapeutics are +31% premarket ($1.8b m/cap Wed PM) based on new data showing LVOT-G reductions for its obstructive hypertrophic cardiomyopathy program, cardiac sarcomere modulator EDG-7500. Would compete with Cytokinetics' drug Camzyos: www.businesswire.com/news/home/20...
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced top-line data of EDG-7500 from the Ph
www.businesswire.com
September 19, 2024 at 12:11 PM
Shares of Edgewise Therapeutics are +31% premarket ($1.8b m/cap Wed PM) based on new data showing LVOT-G reductions for its obstructive hypertrophic cardiomyopathy program, cardiac sarcomere modulator EDG-7500. Would compete with Cytokinetics' drug Camzyos: www.businesswire.com/news/home/20...
#EWTX Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
https://www.stocktitan.net/news/EWTX/edgewise-therapeutics-unveils-the-differentiated-mechanism-of-action-wm7wmuo7qoyg.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EWTX/edgewise-therapeutics-unveils-the-differentiated-mechanism-of-action-wm7wmuo7qoyg.html?utm_source=stocktitan-bluesky&utm_medium=social
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 22, 2026 at 11:00 AM
#EWTX Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
https://www.stocktitan.net/news/EWTX/edgewise-therapeutics-unveils-the-differentiated-mechanism-of-action-wm7wmuo7qoyg.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/EWTX/edgewise-therapeutics-unveils-the-differentiated-mechanism-of-action-wm7wmuo7qoyg.html?utm_source=stocktitan-bluesky&utm_medium=social
Edgewise Therapeutics: Strong Financial Performance and Promising Cardiovascular Pipeline in Q2 2026#USA#Boulder#Cardiovascular#Edgewise_Therapeutics#EDG-7500
Edgewise Therapeutics: Strong Financial Performance and Promising Cardiovascular Pipeline in Q2 2026
Edgewise Therapeutics has reported impressive financial results for Q2 2026 while announcing significant advancements in their cardiovascular programs.
third-news.com
August 6, 2026 at 12:09 PM
Edgewise Therapeutics: Strong Financial Performance and Promising Cardiovascular Pipeline in Q2 2026#USA#Boulder#Cardiovascular#Edgewise_Therapeutics#EDG-7500
Heading to Munich for ESC 2026?
Make sure to connect with Matt Racine, Ph.D., CVrg’s Heart Failure lead! Matt will be on the ground capturing key takeaways across all the latest HF data and trial readouts for our ESC 2026 Conf Report.
For more details / to request a sample: cv-rg.com/conferences/
Make sure to connect with Matt Racine, Ph.D., CVrg’s Heart Failure lead! Matt will be on the ground capturing key takeaways across all the latest HF data and trial readouts for our ESC 2026 Conf Report.
For more details / to request a sample: cv-rg.com/conferences/
August 6, 2026 at 5:03 PM
Heading to Munich for ESC 2026?
Make sure to connect with Matt Racine, Ph.D., CVrg’s Heart Failure lead! Matt will be on the ground capturing key takeaways across all the latest HF data and trial readouts for our ESC 2026 Conf Report.
For more details / to request a sample: cv-rg.com/conferences/
Make sure to connect with Matt Racine, Ph.D., CVrg’s Heart Failure lead! Matt will be on the ground capturing key takeaways across all the latest HF data and trial readouts for our ESC 2026 Conf Report.
For more details / to request a sample: cv-rg.com/conferences/
▲ $EWTX Edgewise Therapeutics: Sold muscular dystrophy business for $1.55B upfront (up to $2.65B total), fully funding EDG-7500 through potential approval. Phase 3 trial starts Q4 2026. GRAND CANYON trial >98% powered. [BULLISH]
July 13, 2026 at 2:30 PM
▲ $EWTX Edgewise Therapeutics: Sold muscular dystrophy business for $1.55B upfront (up to $2.65B total), fully funding EDG-7500 through potential approval. Phase 3 trial starts Q4 2026. GRAND CANYON trial >98% powered. [BULLISH]
🟢 #$EWTX — Clinical Readout
Positive CIRRUS-HCM Part D 12-Week Data Reported for EDG-7500
In the July 13, 2026 press release announcing completion of the sevasemten sale to Servier, Edgewise disclosed that recent 12-week Part D data from the CIRRUS-HCM Phase 2 …
https://biostock.app/symbols/EWTX
Positive CIRRUS-HCM Part D 12-Week Data Reported for EDG-7500
In the July 13, 2026 press release announcing completion of the sevasemten sale to Servier, Edgewise disclosed that recent 12-week Part D data from the CIRRUS-HCM Phase 2 …
https://biostock.app/symbols/EWTX
July 13, 2026 at 12:43 PM
🟢 #$EWTX — Clinical Readout
Positive CIRRUS-HCM Part D 12-Week Data Reported for EDG-7500
In the July 13, 2026 press release announcing completion of the sevasemten sale to Servier, Edgewise disclosed that recent 12-week Part D data from the CIRRUS-HCM Phase 2 …
https://biostock.app/symbols/EWTX
Positive CIRRUS-HCM Part D 12-Week Data Reported for EDG-7500
In the July 13, 2026 press release announcing completion of the sevasemten sale to Servier, Edgewise disclosed that recent 12-week Part D data from the CIRRUS-HCM Phase 2 …
https://biostock.app/symbols/EWTX
#$EWTX shared encouraging Phase 2 CIRRUS-HCM results for EDG-7500, showing strong improvements in symptoms, biomarkers, and diastolic function across both types of HCM. Larger Phase 3 trials will be required before any approval. notreload.xyz/xy/edgewise-...
Edgewise Shares Fall on Positive EDG-7500 Phase 2 HCM Data
Edgewise shared encouraging Phase 2 CIRRUS-HCM results for EDG-7500, showing strong improvements in symptoms, biomarkers, and diastolic function across both types of HCM. Larger Phase 3 trials will be...
notreload.xyz
June 16, 2026 at 12:47 PM
#$EWTX shared encouraging Phase 2 CIRRUS-HCM results for EDG-7500, showing strong improvements in symptoms, biomarkers, and diastolic function across both types of HCM. Larger Phase 3 trials will be required before any approval. notreload.xyz/xy/edgewise-...
#$EWTX +3.6% [JPMorgan boosts Edgewise Therapeutics price target to $45 from $34, maintains Overweight rating. Bullish on EDG-7500 catalysts and strong 2026 setup.] notreload.xyz/jpmorgan-rai...
JPMorgan Raises EWTX Price Target to $45 on 2026 Outlook
JPMorgan boosts Edgewise Therapeutics price target to $45 from $34, maintains Overweight rating. Bullish on EDG-7500 catalysts and strong 2026 setup.
notreload.xyz
March 17, 2026 at 4:30 PM
#$EWTX +3.6% [JPMorgan boosts Edgewise Therapeutics price target to $45 from $34, maintains Overweight rating. Bullish on EDG-7500 catalysts and strong 2026 setup.] notreload.xyz/jpmorgan-rai...
$EWTX +4.6% [Edgewise Therapeutics shares positive safety data from EDG-7500 trial for hypertrophic cardiomyopathy, showing no heart function decline with comprehensive results expected in Q2 2026.] notreload.xyz/edgewise-edg...
Edgewise EDG-7500 Shows Promising Heart Disease Trial Results
Edgewise Therapeutics (EWTX) shares positive safety data from EDG-7500 trial for hypertrophic cardiomyopathy, showing no heart function decline with comprehensive results expected in Q2 2026.
notreload.xyz
December 24, 2025 at 1:23 PM
$EWTX +4.6% [Edgewise Therapeutics shares positive safety data from EDG-7500 trial for hypertrophic cardiomyopathy, showing no heart function decline with comprehensive results expected in Q2 2026.] notreload.xyz/edgewise-edg...
$EWTX +7.7% [H. C. Wainwright began coverage of Edgewise Therapeutics with a Buy rating and a $42 target. The company is developing drugs for muscle diseases, with two candidates: sevasemten and EDG-7500.]
June 30, 2025 at 11:46 AM
$EWTX +7.7% [H. C. Wainwright began coverage of Edgewise Therapeutics with a Buy rating and a $42 target. The company is developing drugs for muscle diseases, with two candidates: sevasemten and EDG-7500.]
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Wednesday, June 17, 2026
By: Salong Debbarma on Wednesday, June 17, 2026
Edgewise reports positive top-line results from Phase II CIRRUS-HCM trial
Edgewise Therapeutics has reported positive top-line data from the 12-week Part D of the Phase II CIRRUS-HCM trial for its cardiac sarcomere modulator, EDG-7500, in patients with both obstructive oHCM...
www.clinicaltrialsarena.com
June 18, 2026 at 10:34 AM
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Wednesday, June 17, 2026
By: Salong Debbarma on Wednesday, June 17, 2026
Feed: "Yahoo Finance"
Published on Monday, March 30, 2026
Published on Monday, March 30, 2026
Edgewise Therapeutics, Inc. (EWTX) PT Increased to $45 at JPMorgan Amid Optimism on EDG-7500 Pipeline
We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Edgewise Therapeutics, Inc. is among the best Robinhood stocks. TheFly reported on March 17 that JPMorgan increased its price target for EWTX from $34 to $45 while keeping an Overweight rating on the stock. The firm also added […]
finance.yahoo.com
March 30, 2026 at 12:49 PM
Feed: "Yahoo Finance"
Published on Monday, March 30, 2026
Published on Monday, March 30, 2026
Edgewise pushes its heart drug into Phase 3 after encouraging mid-stage data.
endpoints.news/edgewise-to-...
endpoints.news/edgewise-to-...
Edgewise to advance heart drug into Phase 3 following mid-stage data update
Edgewise plans to start a Phase 3 trial for HCM drug EDG-7500 in Q4, citing 12-week Phase 2 data showing NT-proBNP response rates above 74% across patient subtypes.
endpoints.news
June 16, 2026 at 7:49 PM
Edgewise pushes its heart drug into Phase 3 after encouraging mid-stage data.
endpoints.news/edgewise-to-...
endpoints.news/edgewise-to-...